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Background: Neonatal dried blood spots (DBS) represent an inexpensive method for long-term biobanking
worldwide and are considered gold mines for research for several human diseases, including those of metabolic,
infectious, genetic and epigenetic origin. However, the utility of DBS is restricted by the limited amount and quality
of extractable biomolecules (including DNA), especially for genome wide profiling. Degradation of DNA in DBS
often occurs during storage and extraction. Moreover, amplifying small quantities of DNA often leads to a bias in
subsequent data, particularly in methylome profiles. Thus it is important to develop methodologies that maximize
both the yield and quality of DNA from DBS for downstream analyses.
Results: Using combinations of in-house-derived and modified commercial extraction kits, we developed a robust
and efficient protocol, compatible with methylome studies, many of which require stringent bisulfite conversion
steps. Several parameters were tested in a step-wise manner, including blood extraction, cell lysis, protein digestion,
and DNA precipitation, purification and elution. DNA quality was assessed based on spectrophotometric
measurements, DNA detectability by PCR, and DNA integrity by gel electrophoresis and bioanalyzer analyses.
Genome scale Infinium HumanMethylation450 and locus-specific pyrosequencing data generated using the refined
DBS extraction protocol were of high quality, reproducible and consistent.
Conclusions: This study may prove useful to meet the increased demand for research on prenatal, particularly
epigenetic, origins of human diseases and for newborn screening programs, all of which are often based on DNA
extracted from DBS.
Keywords: Blood spot, DNA extraction, Epigenetics, Methylome, HM450, Pyrosequencing, Whole bisulfitome
amplification, QIAamp, GenSolve, NucleoSpinBackground
Epigenetic mechanisms, such as DNA methylation, have
been suggested as possible causal pathways linking en-
vironmental exposure to disease. Many of these studies
depend on the epigenome-wide analysis of prospectively
collected samples, in the context of large human co-
horts. As epigenome-wide technologies are becoming
available, the use of such cohort studies will provide
large amounts of information in the coming years. Due
to the general lack of biospecimen collection in observa-
tional human studies, many of these cohorts rely on the* Correspondence: vargash@iarc.fr
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unless otherwise stated.use of dried blood spots (DBS) obtained soon after birth
as the main source of biological information [1].
The use of filter paper for blood collection and analysis
was implemented as early as the 1960s by Guthrie et al.
using dried-blood samples for newborn phenylketonuria
detection [2]. “Guthrie cards” are widely used in many
types of tests, including chemical, serological, and gen-
etic applications [3]. More recently, Flinders Technology
Associates chemically treated filter papers (FTA cards) were
specifically developed for DNA/RNA analyses [4]. These
chemically treated cards allow long-term storage of DNA at
room temperature and are impregnated with denaturants
that guard against oxidation, nuclease and ultraviolet dam-
age, and both bacterial and fungal degradation.
Neonatal DBS are routinely collected in many coun-
tries and represent a cost-effective tool to store preciousral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Ghantous et al. BMC Biotechnology 2014, 14:60 Page 2 of 13
http://www.biomedcentral.com/1472-6750/14/60biological specimens for subsequent studies. However,
reliable profiling the DNA methylome in DBS has proven
to be technically challenging, particularly because such
techniques require stringent bisulfite preprocessing that
can degrade DNA [5]. Other limitations of their use in-
clude the variable degradation of DNA due to storage and
extraction, the usually small amounts of DNA that can be
obtained (typical blood spots are between 6 and 10 mm in
diameter), and the identification of technical artifacts po-
tentially associated with long term storage [6].
Recently, there has been increasing interest in the use
of DBS in DNA methylome analyses, using Methylated
DNA Immunoprecipitaion combined with sequencing
(MeDIP-seq) [7], Methyl-CpG Binding Domain (MBD)
protein-enrichment combined with sequencing (MBD-seq)
[8], and Infinium (Illumina) bead arrays [7,9-11]. The
last version of Illumina’s bead array, Infinium Human-
Methylation450 (HM450) Beadchip, is cost-effective,
requires DNA amounts as low as 300 ng, enables the
detection and quantitation of DNA methylation levels
at 486,685 CpG sites across the genome and represents
one of the most comprehensive microarray methods to
date for investigating the methylome [12]. Three reports
have addressed the utility of HM450 on DBS [7,10,11].
The first report validated the use and the high correlation
between two different methylomic platforms on DBS DNA:
HM450 and MeDIP-seq [7]. The second one generated
good quality methylome-wide data from DBS, as compared
to their matched frozen buffy coat [10]. The third one used
DBS-based HM450 analyses to study the epigenetic effects
of gestational age, as recently demonstrated by our group
[11]. However, none of these studies analyzed methods for
optimized DNA extraction and quality verification from
DBS, both of which represent major upstream steps in the
pipeline for DBS-based research, including epigenetics.
In this report, we tested and developed a range of DNA
extraction methods from neonatal FTA cards, individually
or in combinations. We incorporated or modified protocol
steps that were crucial to increase the DNA yield and qual-
ity from DBS, and additionally tested their efficiency on
Guthrie cards. Moreover, we suggest an optimal protocol
for both, pyrosequencing- and HM450-based, methylation
studies. This work could prove useful in meeting the in-
creased demand for research on prenatal origins of human
diseases and for newborn screening programs.
Results
Optimization of Phases I and II in the DNA
extraction protocols
Limited quantity and quality are important drawbacks
in the use of DNA obtained from DBS, particularly for
epigenome-wide studies. Initially, we ruled out the pos-
sibility of using whole bisulfitome amplification (WGA)
after confirming the introduction of biases, mostly in themiddle range of DNA methylation levels (Additional file 1),
further confirming the recently reported finding by Bundo
et al. [13]. Then, to systematically optimize DNA extraction
from DBS, we divided the different steps of this process
into two phases (Figure 1). Critical steps in Phase I in-
cluded blood extraction off the filter papers, cell lysis
and protease digestion (Figure 1A, left panel). Phase II
included DNA precipitation, purification and elution
(Figure 1A, right panel).
We have previously tested several genomic DNA extrac-
tion methods on DBS, including resin-based, lysis-based and
magnetic bead-based [5]. Lysis- and bead-based methods
were the best, but the latter is not suitable for beadchip
methylation profiling, so it was not considered in this study
[9]. Among lysis-based methods, several commercially avail-
able kits, including QIAamp DNA Micro Kit, GenSolve and
NucleoSpin, have been shown to be efficient for DBS DNA
extraction [10,14,15]. Therefore, we selected these three
kits to optimize the two phases of DNA extraction. This
optimization involved the combination of the different
kits and modifications in several steps of the two protocol
phases (Figure 1B) (described in detail in Additional file 2).
A combination of GenSolve reagents in Phase I and
QIAamp reagents in Phase II (referred to as GQ method)
was set as a reference protocol to which other tested
methods were compared (Tables 1, 2, 3, 4, 5 and 6). In
all pairwise comparisons, two DBS punches from the same
DBS were used, and assessment of quantity and quality
were initially done using Nanodrop (with 260/280 and 260/
230 spectrophotometric ratios as a measure of quality)
(Tables 1, 2, 3, 4 and 5). These DBS were obtained
from the National Children Study (NCS), USA, and
were FTA-type, which preserves well DNA relative to
other types of neonatal cards (Methods), hence, allowing
comparisons across a wide range of DNA extraction
protocols.
DNA yield and quality were consistently better for
the reference GQ protocol when compared to Qiagen
protocol (QQ) (Table 1, p < 0.05). Although DNA yield
was drastically increased when ethanol was used in the
Qiagen precipitation step (Qq, p < 0.001), DNA quality
was still suboptimal compared to GQ, as assessed by
nanodrop (Table 1). In contrast, the combination of
Gensolve and NucleoSpin (GN and Gn) increased the
DNA yield while preserving DNA quality, regardless
of the use of ethanol in the precipitation step (Table 2,
p < 0.05). A similar improvement was observed when
using NucleoSpin kit in both phases of DNA extraction
(NN and Nn) (Table 4, p < 0.001). The extra-small (XS)
versions of NucleoSpin, with column designs specific
for low elution volumes, did not consistently improve
DNA quantity or quality, whether combined or not
with other kits (GN-XS, Gn-XS and NN-XS; Tables 3,
5 and 6), the DNA precipitation buffer changed to
Figure 1 Phases and classification of protocols used to extract DNA from DBS. Two sequential phases, each encompassing three steps, are
outlined (A) and were optimized in the different protocols or method combinations (B) used to extract DNA from DBS. A spin basket is shown
next to Phase I.A and consists of a tube with an embedded perforated basket used to separate blood solutions from the filter papers from which
they were extracted. A silica-gel column with a funnel-shape design is shown next to Phase II.E and often used to elute small volumes (5–30 μl),
as manufactured by Macherey-Nagel and supplied with the extra-small (XS) versions of NucleoSpin kits (B).
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(Table 3, p > 0.05).
Cross-comparisons across the different tested DNA
extraction protocols
DNA quality parameters assessed earlier were based on
DNA 260/280 and 260/230 spectrophotometric ratios.
Two other important quality parameters are DNA de-
tectability by PCR and DNA integrity and size range,
which can be assessed by gel electrophoresis and bioana-
lyzer analyses. DNA from all tested protocols exhibited
detectable PCR bands of a housekeeping gene, GAPDH
(Table 6 and data not shown), hence indicating that theDNA is amplifiable for specific short regions. DNA isolated
by the GQ method exhibited a smear-like profile by gel
electrophoresis, with peak intensity often greater than 1 kilo
base pair (Kbp) (Figure 2 and Table 6). Bioanalyzer smear
analyses confirmed the DNA average size peak to be greater
than 1 Kbp, with an average size ranging across samples be-
tween 4.9-9.7 Kbp (Table 6 and data not shown). Compared
to GQ, all tested protocols often showed more DNA deg-
radation, except for protocol Qq which usually exhibited
similar DNA smear profiles (Figure 2 and Table 6).
Overall comparison of the tested DNA quantity and
quality parameters across the protocols shows that the
best two protocols that at least match GQ in most of the
Table 1 Combinations of Gensolve and Qiagen protocols for DNA extraction from DBS: GQ, QQ and Qq methods
65°C, 65 min
Sample code DNA (ng/μl) DNA (ng) 260/280 260/230 260/280 260/230 Protocol
NCS 11a 21.9 944 2.03 1.04 1.89 1.02 GQ
NCS 11b 3.4 147 1.55 0.19 1.35 0.29 QQ
NCS 12a 19.1 802 1.91 1.19 1.90 1.18 GQ
NCS 12b 6.1 257 1.58 0.36 1.73 0.37 QQ
NCS 13a 8.8 376 1.82 0.68 2.01 0.67 GQ
NCS 13b 2.9 120 2.48 0.25 2.00 0.21 QQ
Precipitation buffer in QQ changed
to ethanol, leading to protocol Qq
NCS 8a 13.9 596 1.88 0.73 1.74 0.79 GQ
NCS 8b 32.1 1379 1.25 0.93 1.28 0.98 Qq
NCS 9a 11.2 493 2.06 0.72 1.93 0.75 GQ
NCS 9b 27.4 1178 1.22 0.75 1.19 0.76 Qq
NCS 10a 12.0 502 2.07 0.88 2.01 0.92 GQ
NCS 10b 31.9 1371 1.47 0.99 1.44 1.01 Qq
NCS 4-1a 15.3 644 2.10 0.83 1.96 0.89 GQ
NCS 4-1b 26.1 1124 0.74 0.58 0.73 0.60 Qq
NCS 4-2a 24.7 1062 1.97 1.05 1.96 1.06 GQ
NCS 4-2b 49.9 2048 0.85 0.73 0.87 0.76 Qq
NCS 4-3a 28.5 1225 2.08 1.22 1.87 1.15 GQ
NCS 4-3b 46.9 1969 1.50 1.23 1.50 1.21 Qq
Two punches, each having 9 mm diameter, were analyzed per DBS. Punches labeled “a” were tested with GQ while their matched pairs, labeled “b”, were tested
with QQ or Qq. When the DNA precipitation buffer in QQ was changed to ethanol, the resultant protocol was termed Qq. Average eluate volume by GQ, QQ or
Qq was 42 μl. Data represent averages of 2–4 readings per sample.
Table 2 Combinations of GenSolve, Qiagen and NucleoSpin protocols for DNA extraction from DBS: GQ versus GN and
Gn methods
65°C, 65 min
Sample code DNA (ng/μl) DNA (ng) 260/280 260/230 260/280 260/230 Protocol
NCS 31a 5.77 242 1.70 0.42 1.55 0.41 GQ
NCS 31b 8.87 426 1.81 0.95 1.54 0.71 GN
NCS 30a 12.8 538 1.88 0.79 1.76 0.76 GQ
NCS 30b 24.4 1171 1.84 1.22 1.90 1.51 GN
NCS 29a 20.7 828 1.85 1.13 1.76 1.00 GQ
NCS 29b 23.1 1063 1.93 1.38 1.85 1.37 GN
Precipitation buffer in GN changed
to ethanol, leading to protocol Gn
NCS 22a 9.85 394 1.81 0.50 1.79 0.48 GQ
NCS 22b 8.00 368 1.90 0.83 1.79 0.75 Gn
NCS 21a 24.3 972 1.83 0.84 1.83 0.90 GQ
NCS 21b 27.7 1274 1.64 0.54 1.83 0.61 Gn
NCS 20a 15.0 600 1.78 0.56 1.77 0.60 GQ
NCS 20b 14.4 662 1.70 0.76 1.74 0.89 Gn
Two punches, each having 9 mm diameter, were analyzed per DBS. Punches labeled “a” were tested with GQ while their matched pairs, labeled “b”, were tested
with GN. When the DNA precipitation buffer in GN was changed to ethanol, the resultant protocol was termed Gn. Average eluate volumes by GQ and GN/Gn
were 42 μl and 47 μl, respectively. Data represent averages of 2–4 readings per sample.
Ghantous et al. BMC Biotechnology 2014, 14:60 Page 4 of 13
http://www.biomedcentral.com/1472-6750/14/60
Table 3 Combinations of GenSolve, Qiagen and NucleoSpin protocols for DNA extraction from DBS: GQ versus GN-XS
and Gn-XS methods
65°C, 65 min
Sample code DNA (ng/μl) DNA (ng) 260/280 260/230 260/280 260/230 Protocol
NCS 28a 20.3 873 1.84 0.95 1.82 0.97 GQ
NCS 28b 37 1813 1.87 0.11 1.78 0.13 GN-XS
NCS 27a 19.4 834 1.85 0.85 1.80 0.90 GQ
NCS 27b 27.9 1339 2.19 0.61 2.26 0.61 GN-XS
NCS 26a 19.7 847 1.83 0.97 1.74 0.93 GQ
NCS 26b 23.7 1161 1.66 0.79 1.77 0.80 GN-XS
NCS 25a 16.3 701 1.9 1.07 1.79 1.07 GQ
NCS 25b 21.7 1042 1.83 0.34 1.96 0.28 GN-XS
NCS 24a 11.3 486 1.82 0.78 1.79 0.82 GQ
NCS 24b 21.6 1037 1.53 0.08 1.48 0.07 GN-XS
NCS 23a 11.9 512 1.18 0.49 1.27 0.54 GQ
NCS 23b 11.4 547 1.44 0.50 1.52 0.42 GN-XS
Precipitation buffer in GN-XS changed
to ethanol, leading to protocol Gn-XS
NCS 19a 30.1 1174 1.53 0.71 1.57 0.81 GQ
NCS 19b 15.1 725 1.49 0.65 1.50 0.70 Gn-XS
NCS 18a 12.2 488 1.81 0.62 1.78 0.64 GQ
NCS 18b 20.4 979 1.30 0.64 1.44 0.72 Gn-XS
NCS 17a 59 2360 1.80 1.37 1.91 1.56 GQ
NCS 17b 42.6 2130 1.65 0.53 1.75 0.57 Gn-XS
Washing volume and frequency
in GN-XS increased
NCS 16a 16.8 823 1.71 0.76 1.80 0.78 GQ
NCS 16b 13.1 707 1.43 0.21 1.55 0.22 GN-XS
NCS 15a 27.1 1382 1.76 1.04 1.79 0.97 GQ
NCS 15b 12.6 668 7.83 0.39 Error * 0.45 GN-XS
NCS 14a 30.3 1545 1.77 1.01 1.83 1.07 GQ
NCS 14b 22.8 1208 2.37 0.60 2.60 0.61 GN-XS
Two punches, each having 9 mm diameter, were analyzed per DBS. Punches labeled “a” were tested with GQ while their matched pairs, labeled “b”, were tested
with GN-XS. When the DNA precipitation buffer in GN-XS was changed to ethanol, the resultant protocol was termed Gn-XS. For NCS 16b, 15a and 14b, the
washing volume was increased from 100 to 500 μl, and washing was performed twice instead of once. Average eluate volumes by GQ and GN-XS/Gn-XS were
42 μl and 48 μl, respectively. Data represent averages of 2–4 readings per sample. * The error represents values out of range.
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Relative to GQ, the only drawback of Qq is its 260/280
DNA ratios (Table 6). Qq 260/280 ratios were always out
of range, indicating that the high Qq DNA quantity mea-
surements recorded spectrophotometrically by nanodrop
may not be accurate. However, quantification with Qubit,
a fluorescent-based method, confirmed the yield in Qq to
be 2.7× higher than in GQ (data not shown). The only
drawback of NN (or Nn) relative to GQ was DNA integrity,
with the DNA size ranges in NN or Nn being lower than in
GQ (Table 6).
In conclusion, protocol GQ seems to be the most robust
among the tested methods across all tested DNA quantity
and quality parameters. Qq can be rather suitable for
applications requiring larger DNA quantities from DBS,
while maintaining large fragment sizes, but in which
260/280 ratios are not a necessity. On the other hand,
protocols NN or Nn may be better suitable for applicationsrequiring larger DNA quantities from DBS, relative to
GQ, while maintaining optimal 260/280 and better
260/230 ratios, but in which large DNA fragment sizes
are not a requirement.
Of note, when GQ was tested on DBS (Guthrie cards,
Whatman 903) from the Tasmanian Infant Health Survey
(TIHS), Australia, dating more than 20 years old, an
average of 66 ± 15 ng (n = 3) of DNA could be extracted
per two punches, each being 1 mm in diameter, with a
mean 260/280 ratio of 1.66 ± 0.02; these DNA quantities
are equivalent to 42.0 ng/mm2 for TIHS, compared to
12.7 ng/mm2 for NCS samples.
Performance of DNA extracted from DBS using
methylome-wide analysis
Methylation probe call index
In order to assess the performance of DNA extracted
from DBS in HM450 methylome-wide analyses, we used
Table 5 Combinations of GenSolve, Qiagen and NucleoSpin protocols for DNA extraction from DBS: GQ versus NN-XS
methods
65°C, 65 min
Sample code DNA (ng/μl) DNA (ng) 260/280 260/230 260/280 260/230 Protocol
NCS 4a 17.5 734 1.98 0.96 1.84 0.98 GQ
NCS 4b 17.3 833 1.72 0.84 1.65 0.78 NN-XS
NCS 5a 17.6 741 1.82 1.05 1.81 1.07 GQ
NCS 5b 12.8 614 1.61 1.02 1.73 1.07 NN-XS
NCS 6a 8.2 328 2.02 0.81 1.79 0.76 GQ
NCS 6b 15.7 756 1.70 0.89 1.70 0.86 NN-XS
NCS 4-10a 22.2 956 1.95 1.21 2.02 1.19 GQ
NCS 4-10b 13.5 660 1.84 1.10 1.85 1.08 NN-XS
NCS 4-11a 19.1 822 1.60 0.85 1.71 0.88 GQ
NCS 4-11b 12.6 618 1.60 1.00 1.58 1.11 NN-XS
NCS 4-12a 10.4 447 1.54 0.74 1.76 0.74 GQ
NCS 4-12b 13.1 657 1.55 0.76 1.70 0.74 NN-XS
Two punches, each having 9 mm diameter, were analyzed per DBS. Punches labeled “a” were tested with GQ while their matched pairs, labeled “b”, were tested
with NN-XS. Average eluate volumes by GQ and NN-XS were 42 μl and 49 μl, respectively. Data represent averages of 2–4 readings per sample.
Table 4 Combinations of GenSolve, Qiagen and NucleoSpin protocols for DNA extraction from DBS: GQ versus NN and
Nn methods
65°C, 65 min
Sample code DNA (ng/μl) DNA (ng) 260/280 260/230 260/280 260/230 Protocol
NCS 1a 25.3 1062 1.84 1.15 1.88 1.18 GQ
NCS 1b 40.0 1802 1.82 1.84 1.90 1.90 NN
NCS 2a 28.8 1209 1.87 1.27 1.89 1.33 GQ
NCS 2b 47.3 2127 1.89 2.00 1.90 1.91 NN
NCS 3a 15.2 638 2.02 1.09 1.93 1.15 GQ
NCS 3b 27.6 1271 1.82 1.59 1.91 1.61 NN
NCS 4-4a 23.0 987 1.93 0.93 1.96 1.03 GQ
NCS 4-4b 30.0 1348 1.85 1.72 1.90 1.81 NN
NCS 4-5a 33.4 1435 1.82 1.01 1.83 1.02 GQ
NCS 4-5b 35.4 1593 1.98 1.94 1.87 1.76 NN
NCS 4-6a 19.9 856 2.01 1.14 1.97 1.10 GQ
NCS 4-6b 33.9 1525 1.93 1.85 1.89 1.82 NN
Precipitation buffer in NN changed
to ethanol, leading to protocol Nn
NCS 4-7a 18.0 774 1.76 0.87 1.86 0.84 GQ
NCS 4-7b 25.7 1155 1.93 1.37 1.81 1.35 Nn
NCS 4-8a 14.7 617 1.99 0.90 1.94 0.91 GQ
NCS 4-8b 24.6 1105 1.92 1.33 1.85 1.42 Nn
NCS 4-9a 26.1 1121 1.90 1.20 1.94 1.26 GQ
NCS 4-9b 39.0 1754 1.95 1.89 1.88 1.77 Nn
Two punches, each having 9 mm diameter, were analyzed per DBS. Punches labeled “a” were tested with GQ while their matched pairs, labeled “b”, were tested
with NN. When the DNA precipitation buffer in NN was changed to ethanol, the resultant protocol was termed Nn. Average eluate volumes by GQ and NN/Nn
were 42 μl and 45 μl, respectively. Data represent averages of 2–4 readings per sample.
Ghantous et al. BMC Biotechnology 2014, 14:60 Page 6 of 13
http://www.biomedcentral.com/1472-6750/14/60
Table 6 Cross-comparisons of DNA quantity and quality parameters among the different tested DNA extraction protocols








QQ Lower (3/3) 175 ± 73 ng Similar (2/3); Worse (1/3) Lower (3/3) NAe Similar (3/3)
Qq Higher (6/6) by 2.0 × Worse (6/6) 0.89 ± 0.22 Similar (6/6) Similar (4/6); Better
(1/6); Worse (1/6)
Similar (6/6)
GN or Gn Higher (4/6) by 1.5 ×; Similar (2/6) Similar (6/6) Similar (4/6);
Higher (2/6)
Worse (4/4) Similar (6/6)
GN-XS or Gn-XS Higher (6/9) by 1.7 ×; Similar (2/9);
Lower (1/9) by 0.4 ×
Similar (6/9); Worse (3/9) Similar (5/9);
Lower (4/9)
Worse (6/6) Similar (9/9)
NN or Nn Higher (8/9) by 1.7 ×; Similar (1/9) Similar (9/9) Higher (9/9)
1.71 ± 0.20
Worse (6/6) Similar (9/9)
NN-XS Similar (2/6); Higher (2/6) by 1.8 ×;
Lower (2/6) by 0.3 ×
Similar (5/6); Worse (1/6) Similar (6/6) Worse (3/5); Similar
(1/5); Better (1/5)
Similar (6/6)
The GQ protocol is set as the reference protocol above all the other protocols to which it is compared. The DNA quantity or quality parameters of the other
protocols are described always in comparison to GQ. DNA yields of QQ were significantly lower than GQ (p < 0.05), those of Qq, GN, Gn, NN and Nn were
significantly higher than GQ (p < 0.05), and those of GN-XS, Gn-XS and NN-XS were not different from GQ (p > 0.05), as compared by paired t-test. For each DNA
parameter described, the counts of hits over the total number of DBS analyzed for that parameter are indicated between parentheses. Table cells highlighted in
bold represent protocol performance that is at least as good as that of GQ.
aQuantities showing less than 20% change from GQ were considered ‘similar’ to GQ. This threshold exceeds the 15.7% average increase in DNA quantities
observed between GQ technical replicates, with an average coefficient of variation of 12.3% (n = 6 pairs of replicates).
bIn protocol pairwise comparisons, 260/280 ratios that were considered ‘similar’ were either both within the optimal 1.7-2.0 range or both outside this range.
Otherwise, the ratio outside the 1.7-2.0 range was considered ‘worse’ relative to that within.
c‘Lower’ and ‘higher’ indicate 260/230 ratio differences of at least 0.30 absorbance units below or above GQ ratios, respectively; otherwise, ratios were considered
‘similar’. The following guidelines were adopted for the 260/230 ratio: optimal and indicating pure DNA if higher than 2.0, acceptable if between 1.5-2.0, and
tolerated if between 1.0-1.49 (Macherey-Nagel GmbH & co. KG, reference 740230).
dDNA integrity refers to DNA size range and level of degradation, as assessed by gel electrophoresis. Ten samples were also reassessed by bioanalyzer, showing
similar relative comparisons to GQ. Every DBS, in which both punches of the tested protocol pairs exhibited high DNA degradation (size range below 1 Kbp), was
excluded from the pairwise comparisons of protocols.
eNA: Not Applicable due to limited quantities of extractable DNA.
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DNA from two sample pairs, each representing two
punches (serving as technical replicates) from the same
DBS, were analyzed by HM450. In addition, DBS pairs
were compared to reference DNA from neonatal blood or
cell lines (Table 7). In all tested samples, whether originat-
ing from neonatal blood, DBS or cell lines, more than 99%Figure 2 DNA integrity and size range as assessed by agarose gel ele
shown in addition to genomic DNA that was isolated from white blood ce
each of the tested protocols are shown, except for protocol QQ in which D
Eight different gel sections are shown and are derived from either the sam
NCS spot were run on the same gel, with the first punch, labeled ‘a’, repres
another unique protocol from the tested set. The two blue lines, represent
the molecular size marker used in each section. The 1000 base pair limit is
epigenetic studies, including Illumina’s HM450 Beadchip array. The results o
summarized in Table 6.of the 485,577 HM450 individual probes were detected,
using the commonly accepted quality control detection
p-value of 0.01, hence, indicating high quality data. The
average beta-values were similar between the technical
replicates NCS 37a and 37b (approximately 0.47 for either)
and between the technical replicates NCS 38a and 38b
(approximately 0.42 for either) (Table 7).ctrophoresis. (A) DNA size markers used to estimate size ranges are
lls (WBC) and used as a positive control. (B) Representative DBS from
NA amounts were insufficient to be analyzed by gel electrophoresis.
e gel or different gels. In each section, two punches from the same
enting protocol GQ and the second punch, labeled ‘b’, representing
ing the 100 and 1000 base pair (bp) size ranges, were set according to
a minimum size range with useful applications in many genetic and
f other DBS analyzed by gel electrophoresis or bioanalyzer are
Table 7 Methylation quality control probe evaluation
Probe Beta-value
Sample Number of CpGs
detected with p < 0.01
Percentage of CpGs
detected with p < 0.01
Average Minimum Maximum
Neonatal Blood DNA NB 1672 485405 99.96 0.4886 0.0012 0.9929
NB 1597 485392 99.96 0.4729 0.0006 0.9947
NB 1842 485358 99.95 0.4911 0.0009 0.9940
NB 1645 485119 99.91 0.4704 0.0011 0.9914
DBS DNA NCS 37a 484990 99.88 0.4712 0.0038 0.9953
NCS 37b 484946 99.87 0.4719 0.0045 0.9916
NCS 38a 483897 99.65 0.4226 0.0005 0.9942
NCS 38b 482519 99.37 0.4240 0.0001 0.9935
Cell Line DNA Cell Line 1 485124 99.91 0.4748 0.0022 0.9926
Cell Line 2 485175 99.92 0.4813 0.0032 0.9920
Cell Line 3 485342 99.95 0.4738 0.0006 0.9926
Cell Line 4 485272 99.94 0.4743 0.0021 0.9934
Three sources of DNA are used in HM450 array: neonatal blood (NB), DBS and cell lines. NB and cell line DNA is of good genomic quality and serves as technical
reference. NB provides DNA from the same tissue origin as DBS, being blood. The cell line DNA is of hepatic origin. The technical pairs are represented by two
punches from each of two blood spots and are labeled as ‘NCS 37a and 37b’ and ‘NCS 38a and 38b’, respectively. Probe p-value was set to 0.01. The percentage
of detected probes (p < 0.01) represents the proportion out of the total of 485,577 probes on the HM450 array. The average, minimum and maximum beta-values
with detection p < 0.01 are shown (background was not subtracted, so minimum beta-values are not exactly zeros).
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quality control probes
For sample and array quality, HM450 array includes 850
quality control (QC) probes. Fifteen QC probes are sample-
independent and 835 QC probes are sample-dependent
[12]. DNA from DBS, neonatal blood or cell lines passed
the described HM450 QC (Additional file 3 and Figure 3).
Background probes, wherever included, produced minimal
signal (maximum limit is 1000 units, as recommended by
Illumina Inc.), and the intended positive signals from the
experimental QC probes were above background, for all
of the three tested DNA sources (Additional file 3 and
exemplified in Figure 3 using non-polymorphic probes,
which are indicative of overall performance). In addition,
performance of DBS samples was similar to that of subsets
taken from reference neonatal blood and cell line samples
(Additional file 4 and Figure 3). Bisulfite conversion effi-
ciency for both, type I and II probes, was high for all tested
samples (Additional file 4) and was confirmed by PCR using
primers that are specific either to bisulfite converted or to
non-modified GAPDH DNA regions (data not shown).
Differential methylation and clustering analyses using
HM450 data
Differential methylation of HM450 beta-values produced
two major clusters (Figure 4). Cell line DNA samples
formed one cluster while DBS and neonatal blood DNA
formed another; this is expected because the cell lines used
are of hepatic tissue origin while both, DBS and neonatal
blood samples, are of blood tissue origin. Within the cluster
of blood biospecimens, all four neonatal blood samplesformed one sub-cluster, which was segregated away from
the DBS sub-cluster. The two punches NCS 37a and 37b,
representing the technical replicates from the same spot
NCS 37, clustered together and away from the other
two technical replicates, NCS 38a and 38b, which also
clustered together (Figure 4). This further supports the
observed higher correlations (p < 0.001, Steiger Z test)
between technical duplicates punched from the same
DBS (r2 range = 0.963-0.990) versus different DBS
(r2 range = 0.949-0.951; Additional file 4A). When the ana-
lysis was limited to the top 1% of probes that showed the
highest variance in M-values (transformed betas) across
any of the four tested DBS, NCS_37a, NCS_37b, NCS_38a
and NCS_38b, the correlation between replicates (r2
range = 0.850-0.972; p < 0.001, Pearson) become signifi-
cantly higher and more predictive of replication (p < 0.001,
Steiger Z test) than the correlation between non-replicates
(r2 range = 0.365-0.371; p < 0.001, Pearson) (Additional file
4B). Similar observations were reported using Spearman
correlations. Moreover, the frequency distributions of delta
M-values (δM) between samples were centred at zero only
between technical replicates (Additional file 4B). Hence,
we can conclude that HM450 analyses using DBS DNA,
extracted using the GQ protocol, is reproducible.
Performance of DNA extracted from DBS using
sequence-specific methylation analysis
The performance of DNA extracted from DBS by the GQ
method was then tested using sequence-specific methyla-
tion analyses. For this purpose, we analyzed the methylation
levels of several CpG sites in Line1 and AluYb8 sequences,
Figure 3 HM450 QC plot using Non-polymorphic probes which
assess overall performance. In the green channel, background
signals are shown in red and pink while positive signals in opaque
and fluorescent green. In the red channel, background signals are
shown in opaque and fluorescent green while positive signals in red
and pink. One non-polymorphic control has been designed for each
of the four nucleotides A, T, C, and G. Four DBS DNA samples are
shown between four neonatal blood and four cell line DNA samples,
in each of the two plots. The DBS samples represent two NCS spots,
37 and 38, each consisting of two tested punches labeled ‘a’ or ‘b’.
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ing transposable elements interspersed across the genome
[16]. The technical replicates, NCS 37a and 37b, showed
similar Line1 and AluYb8 methylation levels at each tested
CpG site, and similar data were observed with the pair,
NCS 38a and 38b (Figure 5A and B). These results show
that inter-replicate variation in methylation levels is min-
imal using several CpG sites in two different loci, Line1 and
AluYb8. Moreover, the observed difference in methylation
levels between the pair NCS 37a and 37b versus NCS 38a
and 38b was consistent at every single CpG tested and
across both, Line1 and AluYb8 loci (p < 0.1 for CpG6 in
Line1 and CpG3 in AluYb8 and p < 0.05 for all other CpGs;
Mann–Whitney test) (Figure 5A and B). These results con-
firm that DNA extracted from DBS using GQ is suitable todetect small methylation differences in a consistent manner
and with low inter-replicate variation.
Discussion
DBS have become an increasingly important tool for
diagnostic purposes and for epigenetic, genetic and
epidemiological research. We have previously tested a
range of commercially available DNA extraction kits for
purifying genomic DNA from fresh and dried blood for
downstream PCR and DNA methylation applications [5].
We found that genomic DNA extraction, using the
ChargeSwitch Forensic DNA Purification kit (Invitrogen),
with subsequent bisulfite modification, using the MethylEasy
kit (Human Genetic Signatures), was best in yielding
bisulfite-converted DNA of sufficient quantity and quality
for downstream candidate-gene DNA methylation analyses,
such as SEQUENOM MassArray EpiTYPER analysis [5].
However, DNA extraction with ChargeSwitch was recently
shown to be not suitable for beadchip methylation profiling,
leading to up to 16% loss of detectable probes in Infinum
HumanMethylation27 (Illumina Inc.) arrays analysis [9].
In relation to the limited amounts of DNA extracted
from DBS, a recent report also pointed to the biases in-
troduced by whole bisulfitome amplification and the
need for careful data interpretation [13], as we have also
observed in this study.
In this work, we have systematically compared different
DNA extraction methods from DBS by dissecting different
phases of extraction and optimizing several steps within
each phase, using commercial and in-house extraction
protocols. For these purposes, we used a homogenous set
of DBS samples, spotted on the same day and stored in a
similar manner, to provide a common platform for cross-
protocol comparisons. Moreover, this study emphasizes
DNA extraction protocols that have particular utility in a
recent technology for studying methylome-wide methyla-
tion, Infinium HM450, and sequence-specific methylation,
by pyrosequencing. The use of DBS for diagnostic and re-
search purposes is not new, but there is a lack of quality
standards for optimizing DNA extraction. This study
suggests different DNA extraction protocols, each hav-
ing specific advantages tailored for specific applications.
Protocol GQ does not extract the highest DNA yield,
but provides DNA in quantities and qualities sufficient for
HM450 methylome-wide and sequence-specific methyla-
tion analyses. With GQ, the 260/280 ratios are consistently
optimal and the extracted DNA is less fragmented relative
to other protocols. Protocol Qq, on the other hand, pro-
duces twice as much DNA as GQ and with similar DNA
integrity. However, 260/280 ratios in Qq are unreliable and
cannot be used for sample selection, particularly for expen-
sive downstream applications. As for protocols NN or Nn,
they extract 1.7 folds more DNA than GQ and show opti-
mal ranges for both, 260/280 and 260/230 ratios. However,
Figure 4 Differential methylation and unsupervised clustering analysis of HM450 data from neonatal blood, DBS and cell line DNA.
Neonatal blood and cell line DNA samples are used as positive controls of good DNA quality for reference comparisons with DNA extracted from
DBS. Neonatal blood and DBS are from different individuals. Four DBS DNA samples are shown between four different neonatal blood and four
different cell line DNA samples. The DBS samples represent two NCS spots, 37 and 38, each consisting of two tested punches labeled ‘a’ or ‘b’.
HM450 beta-values were clustered using Euclidean distance as the dissimilarity index. As shown in the color key, the red and blue signals
represent relatively hypomethylated and hypermethylated regions, respectively.
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to GQ. This may represent a limitation for bead array-
based assays and other DNA methylation assays where
DNA integrity is a requirement. It should be noted
though that 260/280 and 260/230 ratios should be treated
with caution; for example, different contaminants can com-
pensate for each other’s’ deviations, resulting in misleading
optimal 260/280 ratios.
Because the type of purification column was identical
in GQ and Qq, but different from those used in all the
other methods, column nature (Phase II) could be the
reason for the better DNA integrity in the two protocols.
This is further supported by our results showing that in
GQ, changing Phase II (includes column type) while
maintaining Phase I, as in GN/n or GN/n-XS, compro-
mises DNA integrity (Table 6). Changing the DNA pre-
cipitation buffer to ethanol reduces the need in some
protocols to vigorously vortex to dissolve resultant pre-
cipitates but does not seem to enhance DNA integrity
(Figure 2; compare GN versus Gn, GN-XS versus Gn-XS,
and NN versus Nn). However, ethanol, as a precipitatingbuffer, was essential in some protocols to increase the DNA
yield, as in Qq versus QQ (Tables 1 and 6).
Other studies have compared DNA extraction proto-
cols from DBS, but irrespective of epigenetic applications
[17-19]. It is difficult to compare DNA extraction protocols
across different studies due to many reasons, such as dif-
ferences in the structures of filter papers on which blood
was soaked, the storage conditions and year-durations,
and DNA quantifications methods used. However, these
studies used QIAamp DNA Mini Kit (Qiagen) as a refer-
ence method, which is similar to the QQ protocol in this
work, hence, allowing comparisons between our and their
optimized methods. Sjoholm et al. reported that QIAamp
DNA Mini Kit performed the best relative to EZNA
(Omega Bio-Tek), Chelex 100 (AmershamBiosciences)
and alkaline lysis (GenomiPhi DNA Amplification Kit,
AmershamBiosciences) [19]. On the other hand, the in-
house developed DNA extraction methods reported by
Hue et al. and Hollegaard et al. yielded, by Nanodrop
quantification, 3.3 and 2.5 fold more DNA, respectively
than QIAamp DNA Mini Kit [18]. In comparison, the GQ
Figure 5 Methylation analyses of Line1 and AluYb8 loci using
bisulfite pyrosequencing. The methylation levels of six and four
CpG sites were analyzed for Line1 (A) and AluYb8 (B), respectively,
and are expressed as percent of the total number of CpGs analyzed
for each individual CpG site. The DBS samples represent two NCS spots,
37 and 38, each consisting of two tested punches labeled ‘a’ or ‘b’.
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cation, on average 4.6 fold more DNA than matched QQ
samples; in addition, protocols Qq, NN and Nn yielded at
least 1.7 folds more DNA than matched GQ samples.
Moreover, the in-house protocol by Hue et al. produced a
low purity 260/280 average ratio (1.50) [18], while GQ, NN
and Nn ratios were optimal in every tested sample. These
findings support the good performance of our optimized
methods relative to many other in-house and commercial
DNA extraction protocols from DBS. Interestingly, one
study reported a recent method suitable for performing
scalable DNA extractions simultaneously from many
DBS, but with less emphasis on DNA quality and yield
comparisons across different methods [20]. The scale
of our tested methods can be increased by implement-
ing the QIAcube technology (Qiagen), and, with scalable
designs, laser cutting of DBS punches would eliminate
cross-contamination, as has been recently reported [21].Conclusion
This study arises from an international effort across sev-
eral cohorts and working groups aiming to fulfill the
need to systematize quality standards in DNA extraction
and to increase the DNA yield using DBS, particularly
with the advent of high-throughput epigenomic tech-
nology that require high quality and quantity of DNA.
Given the emerging appreciation of DBS collected at
birth as a valuable resource for epigenetic analyses prior
to phenotypic onset, our optimized methods for DNA
extraction with application in methylation analyses have
great potential for diagnostic and research purposes.
Methods
Sample overview
DBS that were used to perform the comparisons across
the DNA extraction protocols were obtained from NCS,
USA, and have been spotted on Flinders Technology
Associates (FTA) mini cards on the same day and dried
in air-sealed containers for approximately two years at
room temperature. Guthrie cards (Whatman 903) from
TIHS, Australia, dating more than 20 years old, were
also used to test the efficiency of the robust protocol GQ.
Both NCS and TIHS samples were heel-prick without an-
ticoagulants added. Permissions from the ethical commit-
tees of the International Agency for Research on Cancer
(IARC), as well as both, NCS and TIHS, were obtained.
TIHS is one of the founder cohorts of the International
Childhood Cancer Cohort Consortium (I4C) [1].
DNA extraction protocols
Combinations of different commercially available DNA
extraction kits were used, including QIAamp DNA Micro
Kit (Qiagen 56304), GenSolve (Gen Vault, GVR110),
NucleoSpin (gDNA clean-up, Macherey-Nagel 740230), and
the extra-small (XS) version of NucleoSpin (gDNA clean-up
XS, Macherey-Nagel 740904). Reported quantifications were
done using Nanodrop, unless indicated otherwise using
Qubit™ dsDNA High Sensitivity Assay, Invitrogen Q32851.
Detailed protocols are included in Additional Methods
(Additional File 2).
Gel electrophoresis and bioanalyzer analysis
Samples were run on a 0.8% agarose gel (Eurobio
GEPAGA07-65) in 1 × Tris Acetate-EDTA buffer and
stained with GelRed. 300 ng of DBS DNA were utilized per
sample in electrophoresis analyses of DNA integrity and size
range. The following DNA size markers were used: 80–
10,000 bp ladder (Thermo SM0403), 500–5,000 bp lad-
der (Takara 3411A), and 100–1,000 bp ladder (Thermo
SM0243). As for bioanalyzer analysis, 500 pg of DNA per
sample was loaded on the chip and analyzed on Agilent
2100 Bioanalyzer, as per manufacturer’s instructions
(Agilent Technology, High Sensitivity DNA Kit, 5067–4626).
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DBS DNA (300 ng) samples were bisulfite converted
using EZ DNA Methylation Kit (Zymo Research D5001)
according to manufacturer’s instructions. To assess the
efficiency of bisulfite conversion, DNA was amplified using
PCR primers that were specific either to bisulfite-converted
or to non-modified DNA, and spanning the region of the
housekeeping gene, GAPDH. The primer pairs spanning
bisulfite-converted GAPDH regions are termed GAPDH-bc
and consisted of the following forward and reverse primers,
respectively: 5’-GTATTTGTTGATGGGTTAAGG-3’ and
5’-ATAAAAACAAATCCCCTACCC-3’. The primer pairs
spanning non-modified GAPDH regions are termed
GAPDH-nm and consisted of the following forward
and reverse primers, respectively: 5’-CTCTTGCTACTCT
GCTCTGG-3’ and 5’-GCTAAGTTTAGCCTGCCTGG-3’.
Efficient conversion is observed when PCR bands are
detected with GAPDH-bc but not with GAPDH-nm for a
given sample. The PCR conditions used were: 95°C 15 min,
[95°C 30 s, 57°C 30 s, 72°C 30 s] × 50 cycles, 72°C 10 min,
and pause 4°C.
Pyrosequencing
DNA methylation analysis by pyrosequencing of bisulfie-
converted DNA was performed as described [22]. Briefly,
the region of interest was amplified with forward and
reverse primers, one of which is biotinylated (btn), and
then the methylation levels of the amplified region were
analyzed using a sequencing primer. The forward, reverse
and sequencing primers used for Line1 were the following,
respectively, and adopted from Daskalos et al. [16]: 5’-btn-
TAGGGAGTGTTAGATAGTGG-3’, 5’-AACTCCCTAACC
CCTTAC-3’ and 5’-CAAATAAAACAATACCTC-3’. The
forward, reverse and sequencing primers used for AluYb8
were the following, respectively: 5’-AGATTATTTTGGT
TAATAAG-3’, 5’-btn-AACTACRAACTACAATAAC-3’
and 5’-GTTTGTAGTTTTAGTTATT- 3’, as previously
described [23].
Illumina Infinium HM450 array and data processing
Infinium HM450 arrays were processed according to man-
ufacturer’s instructions. GenomeStudio was used to analyze
quality controls. The raw colour channels were corrected
using the internal control probes and converted, without
background subtraction and normalization, into abso-
lute methylation levels (beta-values). Data were then
imported into R (3.0.0), using the minfi package version
1.2.0 (http://www.bioconductor.org). Subset-quantile Within
Array Normalisation (SWAN) normalisation was performed
to correct for technical discrepancies between Type I and
Type II [24]. Probes with detection p-values above 0.01 were
considered as background noise and omitted from further
analysis. Sex chromosome-specific probes were eliminated
to minimize gender-specific variation of the X versusY chromosomes [25]. Logarithmic transformation of
the beta-values into M values was done, as previously
described [26]. Statistical tests were performed using
M-values. Clustering plots were generated using the lumi R
package and based on coefficient of variation, which is
calculated by standard deviation divided by mean across
samples [27]. Differentially methylated CpGs were iden-
tified using an F-test in minfi.
Additional files
Additional file 1: Whole bisulfitome amplification.
Additional file 2: Additional Methods.
Additional file 3: Infinium HM450 quality control probes
(minfi package).
Additional file 4: Correlations between technical replicates.
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